Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Journal Title: Медичні перспективи - Year 2015, Vol 20, Issue 3

Abstract

Aim of this study was to analyze molecular genetic and cytogenetic reasons for disease resistance to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) in patients with chronic myeloid leukemia (CML). Material and methods. A group of 32 CML patients with primary or acquired resistance to TKI treatment was investigated. Cytogenetic response was determined by conventional karyotyping with differential banding. Presence of BCR-ABL kinase domain mutations was investigated by direct sequencing. Results and discussion. The frequency of mutations was 37% (12 patients) with prevailing occurrence of mutations with low sensitivity to nilotinib – E255K/V; Т315I; F359V; Y253H. In 47% of the cases (15 patients) additional chromosome aberrations (ACA) were revealed which could also be the reason for TKI resistance in patients without BCR/ABL mutations. Patients with detected mutations of BCR/ABL gene were either switched to nilotinib or treated with increased dose of IM. Cytogenetic response was achieved in only 2 patients with mutations and in 12 patients without them. Frequency of blast crisis development did not differ significantly in both groups. Conclusions. Among the investigated patients with CML resistant to IM BCR/ABL gene mutations were detected in more than third of the cases whereas ACA were found in almost half of the group. Taking into account revealed prevalence of mutations not sensitive to the 2nd generation TKI nilotinib, investigation of mutational status has to be obligatory in all patients for whom treatment correction is considered. Presence of ACA should also be taken into account in patients requiring administration of the second line TKI since they can adversely influence expected treatment response as well.

Authors and Affiliations

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka , I. Selina, H. Usenko

Keywords

Related Articles

Application of the method of ultrasound imaging in the removal of foreign bodies in gunshot wounds

Data on the possibility of using ultrasound diagnostics when removing foreign bodies - bullets and fragments from body tissues during primary or repeated surgical treatment are rather limited. The aim of the research – i...

Клінічний випадок виразкової хвороби дванадцятипалої кишки з перфорацією у породіллі після планового кесаревого розтину

Язвенная болезнь желудка или двенадцатиперстной кишки с перфорацией - тяжелое, угрожающее смертью осложнение язвенной болезни, особенно у беременных или в послеродовом периоде. Возникновение данного осложнения в послерод...

Рак желудка с переходом на пищевод. Диагностика, лечение и предупреждение специальными методами

Захворювання на рак шлунка займає провідне місце в структурі онкологічної патології в Україні і в світі. У статті узагальнені власні результати та літературні дані щодо діагностики, лікування і попередження раку шлунка....

Diagnosis and differential approach to the choice of treatment of pseudocysts of the pancreas

A prospective study of 182 patients with pan¬creatic pseudocyst was conducted. By studying changes in ion-acid-alkaline status of cysts cavity, the correlations between these indicators, indicators of proteinogram of blo...

Изменение микробиоценоза полости рта у студентов с кариесом зубов и хроническим катаральным гингивитом в динамике лечения

У патогенезі захворювань порожнини рота важливу роль відіграє порушення мікроекології. Питання про корекцію мікроекологічних порушень при захворюваннях твердих тканин зубів і запальних захворювань пародонту в пацієнтів м...

Download PDF file
  • EP ID EP90057
  • DOI -
  • Views 120
  • Downloads 0

How To Cite

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka, I. Selina, H. Usenko (2015). Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Медичні перспективи, 20(3), 67-73. https://europub.co.uk/articles/-A-90057